Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.73 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.73 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.58 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.52 |
| ▸ | CASP3 | P42574 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30601923 | 0.98 | TDP1 (0.77) | TDP1L3MBTL1GPR84NR1H3TSHR | |
| SCHEMBL26626715 | 0.98 | TDP1 (0.77) | TDP1L3MBTL1GPR84NR1H3TSHR | |
| SCHEMBL14092273 | 0.95 | TDP1 (0.66) | TDP1L3MBTL1GPR84NR1H3TSHR | |
| SCHEMBL1065287 | 0.88 | CASP3 (0.65) | TDP1L3MBTL1NR1H3TSHRMAPK1 | |
| SCHEMBL916601 | 0.86 | TDP1 (0.96) | TDP1L3MBTL1TSHRMAPK1CYP1B1 | |
| SCHEMBL15955998 | 0.86 | TDP1 (0.67) | TDP1L3MBTL1GPR84TSHRMAPK1 | |
| SCHEMBL9220253 | 0.85 | TDP1 (0.76) | TDP1L3MBTL1CYP1B1CASP3 | |
| SCHEMBL8434811 | 0.85 | TDP1 (1.00) | TDP1L3MBTL1CYP1B1CASP3 | |
| SCHEMBL31035964 | 0.85 | TDP1 (1.00) | TDP1L3MBTL1CYP1B1CASP3 | |
| SCHEMBL29263641 | 0.85 | TDP1 (1.00) | TDP1L3MBTL1CYP1B1CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1663235-B1 | CAPPED PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | PARION SCIENCES INC (US) | 2013-07-24 | — | — | EP | disclosed |
| EP-1663235-B1 | CAPPED PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | PARION SCIENCES INC (US) | 2013-07-24 | — | — | EP | disclosed |
| US-8431579-B2 | Capped pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-8431579-B2 | Capped pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-8431579-B2 | Capped pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2013-04-30 | — | — | US | disclosed |
| EP-2465852-A1 | Capped pyrazinoylguanidine sodium channel blockers | Parion Sciences, Inc. (US) | 2012-06-20 | — | — | EP | disclosed |
| EP-2465852-A1 | Capped pyrazinoylguanidine sodium channel blockers | Parion Sciences, Inc. (US) | 2012-06-20 | — | — | EP | disclosed |
| US-8022210-B2 | 3-Aminopyrazine-2-carbonylguanidine derivatives; (4-{4-[N'-(3,5-Diamino-6-chloropyrazine-2-carbonyl)guanidino]butyl}phenoxy)acetic acid 2-piperidin-1-yl-ethyl ester; hydration of mucous membranes; respiratory system and gastrointestinal disorders; skin, eye and vaginal dryness; hypotensive agents; asthma | PARION SCIENCES, INC. (US) | 2011-09-20 | — | — | US | disclosed |
| US-8022210-B2 | 3-Aminopyrazine-2-carbonylguanidine derivatives; (4-{4-[N'-(3,5-Diamino-6-chloropyrazine-2-carbonyl)guanidino]butyl}phenoxy)acetic acid 2-piperidin-1-yl-ethyl ester; hydration of mucous membranes; respiratory system and gastrointestinal disorders; skin, eye and vaginal dryness; hypotensive agents; asthma | PARION SCIENCES, INC. (US) | 2011-09-20 | — | — | US | disclosed |
| US-8022210-B2 | 3-Aminopyrazine-2-carbonylguanidine derivatives; (4-{4-[N'-(3,5-Diamino-6-chloropyrazine-2-carbonyl)guanidino]butyl}phenoxy)acetic acid 2-piperidin-1-yl-ethyl ester; hydration of mucous membranes; respiratory system and gastrointestinal disorders; skin, eye and vaginal dryness; hypotensive agents; asthma | PARION SCIENCES, INC. (US) | 2011-09-20 | — | — | US | disclosed |
| US-20060052395-A1 | Capped pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2006-03-09 | — | — | US | disclosed |
| US-20060040954-A1 | Soluble amide & ester pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2006-02-23 | — | — | US | disclosed |
| EP-1599096-A2 | HETERO SUBSTITUED SODIUM CHANNEL BLOCKERS | Parion Sciences, Inc. (US) | 2005-11-30 | — | — | EP | disclosed |
| US-20050234072-A1 | Capped pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC., DURHAM, NC | 2005-10-20 | — | — | US | disclosed |
| US-20050228182-A1 | Capped pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2005-10-13 | — | — | US | disclosed |
| US-20050090505-A1 | Methods of reducing risk of infection from pathogens | JOHNSON MICHAEL R (US) | 2005-04-28 | — | — | US | disclosed |
| WO-2005034847-A2 | METHODS OF REDUCING RISK OF INFECTION FROM PATHOGENS | PARION SCIENCES, INC. (US) | 2005-04-21 | — | — | WO | disclosed |
| US-20050080091-A1 | Capped pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2005-04-14 | — | — | US | disclosed |
| WO-2005018644-A1 | CAPPED PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2005-03-03 | — | — | WO | disclosed |
| WO-2004073629-A2 | HETERO SUBSTITUED SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2004-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080091-A1 | Capped pyrazinoylguanidine sodium channel blockers | CACNA1B, CACNA1C, HCN4 | TDP1 4325/4885L3MBTL1 4335/4885GPR84 2794/4885 |
| US-20050234072-A1 | Capped pyrazinoylguanidine sodium channel blockers | CACNA1B, CACNA1C, HCN4 | TDP1 4325/4885L3MBTL1 4335/4885GPR84 2794/4885 |
| US-20060040954-A1 | Soluble amide & ester pyrazinoylguanidine sodium channel blockers | SCN2A, CACNA1B, HCN4 | TDP1 4353/4885L3MBTL1 4663/4885GPR84 651/4885 |
| US-20050228182-A1 | Capped pyrazinoylguanidine sodium channel blockers | CACNA1B, CACNA1C, HCN4 | TDP1 4325/4885L3MBTL1 4335/4885GPR84 2794/4885 |
| US-20050090505-A1 | Methods of reducing risk of infection from pathogens | KCNN3, KCNN1, KCNN2 | TDP1 3629/4885L3MBTL1 1373/4885GPR84 3359/4885 |
| US-20060052395-A1 | Capped pyrazinoylguanidine sodium channel blockers | CACNA1B, CACNA1C, HCN4 | TDP1 4325/4885L3MBTL1 4335/4885GPR84 2794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.